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HyperammonemiaHepatic transport and metabolism of glutamate and glutamine are regulated by intervention of several
proteins. Glutamine is taken up by periportal hepatocytes and is the major source of ammonia for urea
synthesis and glutamate for N-acetylglutamate (NAG) synthesis, which is catalyzed by the N-acetylglutamate
synthase (NAGS). Glutamate is taken up by perivenous hepatocytes and is themain source for the synthesis of
glutamine, catalyzed by glutamine synthase (GS). Accumulation of glutamate and ammonia is a common
feature of chronic liver failure, but mechanism that leads to failure of the urea cycle in this setting is unknown.
The Farnesoid X Receptor (FXR) is a bile acid sensor in hepatocytes. Here, we have investigated its role in the
regulation of the metabolism of both glutamine and glutamate. In vitro studies in primary cultures of
hepatocytes from wild type and FXR−/−mice and HepG2 cells, and in vivo studies, in FXR−/−mice as well as
in a rodent model of hepatic liver failure induced by carbon tetrachloride (CCl4), demonstrate a role for FXR in
regulating this metabolism. Further on, promoter analysis studies demonstrate that both human and mouse
NAGS promoters contain a putative FXRE, an ER8 sequence. EMSA, ChIP and luciferase experiments carried
out to investigate the functionality of this sequence demonstrate that FXR is essential to induce the expression
of NAGS. In conclusion, FXR activation regulates glutamine and glutamate metabolism and FXR ligands might
have utility in the treatment of hyperammonemia states.icina Clinica e Sperimentale,
2 Perugia, Italy. Tel./fax: +39
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
The amino acids glutamine and glutamate participate in multiple
biochemical pathways and are at the center of hepatic amino acid
metabolism [1,2]. In the liver (Fig. 1), glutamine is transported into
periportal hepatocytes by the solute carrier (SLC)-1A5 (also named
ASCT2) [2,3] and is used to synthesize glutamate. This reaction is
catalyzed by the enzyme glutaminase (GLS). Then, glutamate can be
converted to N-acetylglutamate (NAG) by the activity of the enzyme
NAG synthetase (NAGS) [4,5]. NAG is an obligatory co-activator of
carbamoyl phosphate synthetase-I (CPS-I), the rate limiting enzyme
in the urea synthesis (5). Alternatively, glutamate can be converted
into α-ketoglutarate (αKG) on a reaction that produces ammonia,
catalyzed by the enzyme glutamate dehydrogenase (GDH) [6]. In
perivenous hepatocytes, the site of hepatic glutamine synthetase (GS)activity, glutamate is taken up by the transporters SLC1A2 (also
named EAAT2) and SLC1A4 (also named ASCT1) and is primarily used
to synthesize glutamine [7].
Farnesoid X Receptor (FXR) is a member of nuclear receptor
superfamily initially characterized in the liver for its ability to regulate
genes involved in bile acid synthesis and cholesterol metabolism,
detoxiﬁcation and excretion [8,9]. In addition, FXR plays a role in
regulating genes involved in lipid metabolism, inﬂammatory response
as well as in insulin regulated pathways [10–12]. FXR regulates gene
transcription as a heterodimer with the 9-cis retinoic acid receptor
(RXR) by binding DNA responsive elements (FXREs) composed by an
inverted repeat of the sequence AGGTCA (consensus) separated by one
nucleotide (IR-1), a direct repeat sequence separated by one nucleotide
(DR-1) or an everted repeat sequence separated by eight nucleotides
(ER-8) [13]. Bile acids, the steroid end-products of the cholesterol
metabolism, are FXR ligands: in particular FXR is strongly activated by
the primary bile acid chenodeoxycholic acid (CDCA) with an EC50 of
≈10 μmol/L [10]. In a recent work it has been demonstrated that FXR is
directly involved in the transcription of the glutamine transporter
ASCT2 in HepG2 as an IR-1 sequence was found in the promoter of the
human ASCT2 gene [14]. However it is unknown whether bile acids
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Fig. 1. Diagrammatic representation of glutamine and glutamate metabolism associated with urea cycle across the liver sinusoid. NAGS: N-acetylglutamate synthase; GDH:
Glutamate dehydrogenase; CPSI: Carbamyl−phosphate-synthase-I; ASCT1: solute carrier family 1 member 5; EAAT2: solute carrier family 1 member 2; ASCT2: solute carrier family
1 member 4; GLS: Glutaminase; GS: Glutamine synthase; FXR: Farnesoid X receptor.
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glutamate metabolism.
In the present study we provide the ﬁrst evidence that FXR is a
direct regulator of genes involved in glutamine/glutamate metabo-
lism. More speciﬁcally, we show that the NAGS promoter contains an
FXRE, an ER-8 sequence (TGAGCTCAGGCAACAGGACA), whose muta-
tion abrogates the ability of FXR ligands to increase NAGS transcrip-
tion. Further on we observed that FXR activation directly stimulates
urea production in vivo and in vitro. In conclusion, these data suggest a
potential therapeutic role for FXR ligands in the treatment of
hyperammonemia associated with liver diseases.2. Material and methods
2.1. Isolation and culture of primary hepatocytes from FXR wild type and
FXR deﬁcient mice
Primary hepatocytes were isolated from C57BL6 wild type (Harlan
Nossan) and FXR knockout animals (obtained from Gonzalez F.J. [15])
Brieﬂy, mice were anesthetized with pentobarbital sodium solution
(50 mg/kg i.p.), the inferior vena cava cannulated and the liver ﬁrst
perfused in situwith an oxygenated Hanks' buffer salt solution (HBSS)
containing 100 U/mLpenicillin/streptomycin (Invitrogen,Milan, Italy)
and 0.04% collagenase-D (Roche, Milan, Italy) pH 7.4 (8 mL/min, 37 °C
for 10 min), followed by perfusion with oxygenated HBSS containing
1 mM Ca2+ and Mg2+, penicillin/streptomycin (100 U/mL), and 0.04%
collagenase II (Sigma, Milan, Italy), pH 7.4 for 10 min. The liver was
removed and then gently minced in HBSS containing 1 mM Ca2+ and
Mg2+, penicillin/streptomycin (100 U/mL), and 1×10−7 M insulin
(Sigma, Milan, Italy) pH 7.4. The liver cell suspensionwas then ﬁltered
with Falcon cell strainers (40, 70, and 100 μm; Becton Dickinson,
Milan, Italy) and centrifuged at 50×g for 2 min. From the isolation of
one mouse liver, a typical yield was about 50–60×106 hepatocytes.
Cell viability, as determined by trypan blue exclusion, was generally
N90%, and cell purity was N95% hepatocytes. Cells were plated on 6-
well plates (6×105 cells/well) or 24-well plates (8×104) (Biocoat
Collagen I cellware plates; Becton Dickinson, Milan, Italy) inWilliam's
Medium E (Invitrogen, Milan, Italy) containing 10% fetal bovine serum
(Invitrogen, Milan, Italy), 100 U/mL penicillin/streptomycin, and1×10−7 M insulin and cultured at 37 °C with 5% CO2. After an initial
4-h attachment period, cultures were washed with phosphate-
buffered saline (PBS) and then stimulated with CDCA (10 μmol/L) or
with the synthetic FXR ligandGW-4064 (5 μmol/L) for 18 h. At the end
of treatment RNA was extracted to value relative mRNA expression of
ASCT1, ASCT2, EAAT2, NAGS, GDH, CPSI, GLS and GS by Real-Time PCR.
To value urea synthesis primary hepatocytes were treated 18 h with
NH4Cl (10 mmol/L), GW-4064 (5 μmol/L), with the combination of
NH4Cl plus GW-4064 or with the combination of NH4Cl plus N-
acetylglutamate (5 mmol/L).2.2. Animal studies
All animal procedures were approved by the Animal Study
Committees of the University of Perugia. FXR−/− mice (obtained from
Gonzalez F.J. [15]), and their backgrounds, C57BL/6jmice (Charles River
Breeding Laboratories,Monza, Italy) were housedwith a 12 h light/12 h
dark cycle with free access to water and standard laboratory chow diet.
Cirrhosis induced by carbon tetrachloride (CCl4) was used as an
experimental model of hyperammonemia. Cirrhosis was induced by
administering phenobarbital sodium (35 mg/dL) into the drinking
water for 3 days, followed by intraperitoneal injection (i.p.) of
100 μL/100 g body weight of CCl4 in an equal volume of parafﬁn oil
twice aweek for 6 weeks.Mice administered CCl4were treated by i.p. of
CDCA, 10 mg/kg bodyweight, while control animalswere administered
an equal volume of vehicle (methyl–cellulose). At the end of the study,
mice were sacriﬁced and the livers removed to measure the relative
mRNAexpressionof ASCT1, ASCT2, EAAT2,NAGS, GDH, CPSI, GLSandGS
by Real-Time PCR. Blood samples were collected for plasma urea
determination.2.3. Urea and nitrogen assay
Urea concentration in plasma samples and culture mediums was
measured by the QuantiChrom™ Urea Assay Kit (BioAssay Systems,
Hayward, USA) according to the manufacturer's speciﬁcations. Serum
levels of ammonium were measured by clinical chemistry testing
performed on a Hitachi 717 automatic analyzer (Roche, Milan, Italy).
Table 1
Primers used for quantitative Real Time PCR analysis.
Gene Forward Reverse
Human GAPDH gaaggtgaaggtcggagt catgggtggaatcatattggaa
Human ASCT1 gcattctccaccacctgaat gcgatgtctcctcctcagac
Human ASCT2 catcctgggcttggtagtgt gatccaggagaccagaacca
Human EAAT2 cgccatctttatagcccaaa cagaatgaggagcatggtga
Human NAGS acaaaagaacggcagcagat ggaccccttgttgcataaga
Human GDH ggaggttcaccatggagcta tggtgctggcataggtatca
Human CPSI acatccagccgaattggtag ctggagggttcagacagctc
Human GLS ttccgaaagtgtgtgagcag ccacaggtctgggtttgact
Human GS tgatcctaagcccattcctg tcataggcacggatgtggta
Mouse GAPDH ctgagtatgtcgtggagtctac gttggtggtgcaggatgcattg
Mouse ASCT1 gggaacgtgaccaaagagaa ggcctcattgaaggaattga
Mouse ASCT2 caaccaaagaggtgctggat cctccacctcacagagaagc
Mouse EAAT2 ggcaatcccaaactcaagaa gtggtattggcctcctcaga
Mouse NAGS cttcggagagacctgcaaac ccgaaccagaagaagatcca
Mouse GDH ggccgattgaccttcaaata tcctgtcctggaactctgct
Mouse CPSI aggcaccaccattacctcag cgggttcatcaggactgttt
Mouse GLS ccgtggtgaacctgctattt tgcgggaatcatagtccttc
Mouse GS cattgacaaactgagcaagagg aagtcgttgatgttggaggttt
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HPLC–MS/MS
The amount of NAG in the livers of FXR+/+ and FXR−/− mice was
quantiﬁed in frozen tissues. 30 mg liver samples were homogenized
with 400 μL of 2 M perchloric acid (PCA), sonicated and proteins were
precipitated by centrifugation at 20,000 g for 10 min at 4 °C. The
supernatants were neutralized with 400 μL of 2 M KOH/0.6 M MES
solution. After centrifugation (20,000 g, 10 min, 4 °C), the superna-
tants were removed to glass vials and dried under N2 stream. The
obtained residues were taken up in a mix of 150 μL of distilled H2O, 2%
HCOOH and 0.05% TFA. An aliquot of 25 μLwas injected into the HPLC–
MS system LTQ XL ThermoScientiﬁc equipped with Accelera 600
Pump and Accelera AutoSampler system. The mixture was separated
on a Jupiter 5μ C18 column from Phenomenex (150×2.00 mm) using
as mobile phases H2O—0.05% TFA—2% HCOOH (eluent A) and ACN—
0.05% TFA—2% HCOOH (eluent B). The eluents were linearly changed
from 0% B to 20% B within 10 min; the columns ﬂow rate was set at
200 μL/min. The mass-spectrometer was set to operate with an ESI
ionization source in positive mode. The capillary temperature was
kept at 250 °C, the sheath gas ﬂow rate and the auxiliary ﬂow rate
were set at 15 and 5, respectively. Instrument optimization was
performed by direct infusion and manual tuning. Detection of NAG
was performed using the selected reaction-monitoring mode (SRM).
The transition of the NAG molecule to its corresponding product ions
was recorded at m/z 190.2→131.2 (−CH3CONH2). The collision
energy used was set at 35. Results are the mean±SD of the value
obtained for each independent animal in the respective group.
(*pb0.05; **pb0.001)
2.5. Cell culture
HepG2 cells were grown at 37 °C in E-MEM containing 10% FBS, 1%
L-glutamine and 1% penicillin/streptomycin. Cells were serum starved
and treated 18 h with 10 μmol/L CDCA or 5 μmol/L GW4064. At the
end of treatment RNA was extracted to value relative mRNA
expression of ASCT1, ASCT2, EAAT2, NAGS, GDH, CPSI, GLS and GS
by Real-Time PCR.
2.6. Real-Time PCR
Total RNA was isolated from cells or liver using the TRIzol reagent
(Invitrogen, Milan, Italy), puriﬁed of the genomic DNA by DNase-I
treatment (Invitrogen, Milan, Italy) and random reverse-transcribed
with Superscript II enzyme (Invitrogen, Milan, Italy) according to the
manufacturer's speciﬁcations. Fifty ng templatewas used in 25 μL ﬁnal
volume reaction of Real-Time PCR contained the following reagents:
0.2 μmol/L of each primer and 12.5 μL of 2X SYBR Green qPCR master
mix (Invitrogen, Milan, Italy). All reactions were performed in
triplicate and the thermal cycling conditions were: 2 min at 95 °C,
followed by 40 cycles of 95 °C for 20 s, 55 °C for 20 s and 72 °C for 30 s
in iCycler iQ instrument (BioRad, Milan, Italy). The results of Real-
Time PCR were normalized with the housekeeping gene GAPDH and
expressed as 2−(ΔΔCt). All PCR primers were designed using software
PRIMER3-OUTPUT using published sequence data from the NCBI
database (Table 1).
2.7. Chromatin immunoprecipitation
10×106 HepG2 cells were stimulated 18 hwith 10 μmol/L CDCA or
received the vehicle alone (1% DMSO). At the end of the treatment
cells were cross-linked with 1% formaldehyde at room temperature
for 10 min. The reaction was terminated by incubation with glycine at
the ﬁnal concentration of 125 mM for 5′ at room temperature. Cells
were lysed in 500 μL ChIP Lysis Buffer (1% SDS, 10 mmol/L EDTA,
50 mmol/L Tris–HCl pH 8), sonicated and then pelleted at 13,000 rpm1′ at 4 °C. Supernatant was collected, diluted with ChIP dilution buffer
(0.01% SDS, 1% Triton X-100, 1.2 mmol/L EDTA pH 8, 16.7 mmol/L
Tris–HCl pH 8, 167 mmol/L NaCl) and 20 μg chromatin was immuno-
precipitated with an anti-FXR antibody (H-130; Santa Cruz, CA, USA)
or with an anti-IgG as negative control. Immunoprecipitates were
collected with protein A beads (GE Healthcare, Milan, Italy) and
washed sequentially, ﬁrst with a low-salt wash buffer (0.1% SDS, 1%
Triton X-100, 2 mmol/L EDTA pH 8, 20 mmol/L Tris–HCl pH 8,
150 mmol/L NaCl) and then with high-salt wash buffer (0.1% SDS,
1% Triton X-100, 2 mmol/L EDTA pH 8, 20 mmol/L Tris–HCl pH 8,
500 mmol/L NaCl). DNA was eluted with 500 μL Elution Buffer (1%
SDS, 0.1 mol/L NaHCO3) 30′ at 65 °C and the cross-linking reactions
were reversed by adding 20 μL NaCL 5 mol/L and by heating the
mixture overnight at 65 °C. The DNA was recovered from immuno-
precipitated material by proteinase K treatment at 65 °C for 1 h
followed by phenol/chloroform (1:1) extraction, ethanol precipitation
and dissolved into 50 μL of water. Five microliters was used for
quantitative real-time PCR of the NAGS promoter with the following
forward and reverse primers: CACAGAATTCCTCAAGCTGG and CAGA-
GAAGAAGGGACTGTAG. Raw data analysis was performed as follows:
ΔCt was calculated versus the input DNA concentration; ΔΔCt was
versus unstimulated cells immunoprecipitated with the anti-IgG
antibody (experimental condition set as 1.0); the relative expression
was calculated as 2−(ΔΔCt).
2.8. Electrophoretic mobility shift assay
Preparation of nuclear extract from HepG2 cells not treated or
administered CDCA 10 μmol/L for 18 h was done using NE-PER
(Pierce, Rockford, IL, USA). The probe used for EMSA (NAGS-ER8:
TTTTGAGCTCAGGCAACAGGACAGAC) was labeled with biotin using
Biotin 3′ end DNA labeling kit (Pierce, Rockford, IL, USA) according to
the manufacturer's instructions. For EMSA, 10 μg of nuclear extract
was incubated with 20 fmol of the NAGS-ER8 probe in a total volume
of 20 μL of binding buffer (50 mmol/L NaCl, 10 mmol/L Tris–HCl, pH
7.9, 0.5 mmol/L EDTA, 10% glycerol, 1 μg of poly dI-dC) for 20 min at
room temperature. For competition assays, an excess of NAGS-ER8
unlabeled oligonucleotide was pre-incubated with nuclear extract
from CDCA-treated cells for 15 min prior to the addition of the biotin-
labeled probe. For antibody-mediated supershift assay, extracts from
stimulated cells were pre-incubated with 1 μg anti-FXR antibody (H-
130; Santa Cruz, CA, USA) at room temperature for 15 min before the
addition of the biotin-labeled probe. The reactions were loaded on a
6% polyacrylamide non-denaturing gel in 0.5×Tris–borate–EDTA
buffer and electrophoresed for 1 h at 100 V. The protein/DNA
complexes were then transferred to positively charged nylon
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and the supershift was detected using the Chemiluminescent Nucleic
Acid Detection Module (Pierce, Rockford, IL, USA).
2.9. Plasmid construction, mutagenesis and luciferase assay
The human 5′ ﬂanking region of NAGS gene, consisting of −558
to −332 base pairs with respect to the transcriptional start site
ATG, was ampliﬁed by PCR from HepG2 genomic DNA (primers:
atcgctcgagcacagaattcctcaagctggtacccagtga and cccgaagcttcagagaa-
gaagggactgtaggtggctttga). PCR product was puriﬁed, double
digested with Xho-I Hind-III enzymes and cloned into pGL3
promoter vector (Promega). The mutagenesis of ER8 responsive
element was performed with the Quik change site directed
mutagenesis kit (Stratagene). The primers used for the ER8
mutagenesis were the following: cattcattaggatcttttttaaactcaggcaa-
caggacagacaag and cttgtctgtcctgttgccygagtttaaaaaagatcctaatgaatg.
Primer sequences used for cloning three tandem repeats of the
NAGS-ER8 wild type and mutated sequence into pGL3 promoter
vector were the following: NAGS(ER8)3X: atcgggtacctgagctcaggcaa-
caggacatgagctcaggcaacaggacatgagctcaggcaacaggacactcgagatcg
and cgatctcgagtgtcctgt tgcctgagctcatgtcctgttgcctgagctc-
atgtcctgttgcctgagctcaggtacccgat; NAGS(ER8mutated)3X:
a t c g g g t a c c t a a a a t c a g g c a a c a g g a c a t a a a a t caggcaacagg -
g g t a c c t a a a a t c a g g c a a c a g g a c a t a a a a t c a g g c a a c a g g -
t a a a a t c a g g c a a c a g g a c a t a a a a t c a g g c a a c a g g -
a a a a t c a g g c a a c a g g a c a t a a a a t c a g g c a a c a g g -
a c a t a a a a t c a g g c a a c a g g a c a c t c g a g a t c g a n d
cgatctcgagtgtcctgttgcctgattttatgtcctgttgcctgattttatgtcctgttgcctgattt-
ttatgtcctgttgcctgattttatgtcctgttgcctgattttaggtacccgat. These primers
were oligo-annealed and the resulting double strand oligos were
digested and cloned Kpn-I Xho-I into pGL3 promoter vector. For
luciferase assay, cells were transfected with Fugene HD (Roche, Milan,
Italy) Luminescence was measured with the Glomax 20/20 lumin-
ometer (Promega, Milan, Italy). Luciferase activities were normalized
for transfection efﬁciencies by dividing the relative light units by β-
galactosidase activity.
2.10. Western blot anti-NAGS
Total proteins extracted from liver specimens or cells were
solubilized in NuPAGE sample buffer (Invitrogen) containing sample
reducing agent (Invitrogen) and then separated by SDS PAGE. The
proteins were then transferred to nitrocellulose membranes (Bio-
Rad) and probed with primary antibodies NAGS (Abcam) and α-
tubulin (Sigma). The anti-immunoglobulin G horseradish peroxidase
conjugate (Bio-Rad) was used as the secondary antibody, and speciﬁc
protein bands were visualized using Super Signal West Dura (Pierce),
following the manufacturer's suggested protocol.
2.11. Statistical analysis
All values are expressed as mean±SE of n observations per group.
Comparisons of more than two groups were made with a one-way
ANOVA with post-hoc Tukey's test. Differences were considered
statistically signiﬁcant if P was b0.05.
3. Results
3.1. FXR null mice have an impaired expression of genes involved in
glutamine and glutamate transport and metabolism
We have ﬁrst examined whether FXR gene ablation results in an
altered expression of genes involved in glutamine and glutamate
metabolism. Results from this experiment demonstrate that FXR gene
ablation leads to a signiﬁcant reduction in the expression of theglutamine transporter ASCT2, while the expression of the glutamate
transporters, EAAT2 and ASCT1, were unchanged in FXR−/− mice in
comparison with wild type mice. (Fig. 2A, n=6; Pb0.05). In addition,
while the expression of GDH in FXR−/− livers was increased by
approximately 3 folds in comparison with wild type mice (n=6;
Pb0.05), the liver expression of NAGS, mRNA and protein, was
reduced by ~40% (Fig. 2A and B, n=6; Pb0.05). No changes were
found in the expression of CPSI, the enzyme mediating the ﬁrst and
limiting step of urea cycle, and GS, while the expression of GLS was
slightly reduced in FXR−/− mice (Fig. 2A, n=6; Pb0.05). Because
these changes predict that FXR gene ablation could result in an altered
nitrogen balance, i.e. a reduced synthesis of urea, we have assessed
blood levels of urea and ammonia in wild type and FXR−/− mice.
Results shown in Fig. 2C and D demonstrate that at the age of
12 weeks, FXR−/− mice have a reduced plasma levels of urea and
slight, but signiﬁcant, increase of plasma ammonia levels (Fig. 2C and
D, n=6; Pb0.05). These changes are in agreement with another
investigation we made that in FXR−/− mice the production of NAG,
the co-activator of CPSI, is basally reduced (Fig. 2E, n=6; Pb0.05).
3.2. FXR activation regulates the expression of genes involved in
glutamine and glutamate transport and metabolism and enhances urea
synthesis in primary mouse hepatocytes
We have next investigated the effects of natural and synthetic FXR
agonists on genes involved in glutamate metabolism in hepatocytes
isolated from FXR+/+ and FXR−/−mice. As shown in Fig. 3A, treating
FXR+/+ hepatocytes with CDCA or GW-4064 resulted in a robust
induction of mRNA expression of glutamine and glutamate trans-
porters (ASCT1, ASCT2 and EAAT2) as well as of NAGS and GLS (n=4;
Pb0.05). Furthermore, the expression of GDH mRNA was down-
regulated following exposure to natural or synthetic FXR agonists
(n=4; Pb0.05), while CPSI and GS mRNA were unchanged. By
contrast, as shown in Fig. 3B, exposure of primary mouse hepatocytes
isolated from FXR−/− mice to CDCA or GW-4064 failed to reproduce
these changes. Because treatment of primary hepatocytes with NH4Cl
stimulates urea synthesis [16,17], we have investigated urea gener-
ation by FXR+/+ and FXR−/− hepatocytes challenged with NH4Cl in
combination with an FXR agonist. As shown in Fig. 4A, production of
urea in this setting was induced following exposure of FXR+/+
hepatocytes to NH4Cl. The synthetic FXR ligand GW-4064 was as
effective as NH4Cl in stimulating urea synthesis and the combination
of two exerted an additive effect (Fig. 4; white bars, n=4; Pb0.05). By
contrast, the urea production induced by both NH4Cl, or GW-4064 or
the combination of the two was markedly attenuated in FXR−/−
hepatocytes (Fig. 4, black bars, n=4, Pb0.05) suggesting a role for
FXR as regulator of the urea cycle. In order to evaluate whether the
increased urea synthesis was really a consequence of increased NAGS
expression we performed an experiment in FXR+/+ and FXR−/−
hepatocytes administered with NH4Cl in presence of saturating
amount of NAG. As shown in Fig. 4B, urea production was the same
in these cells, indicating that induction of NAGS by FXRwas crucial for
stimulating urea synthesis. Similar data (i.e. RT-PCR results and urea
determinations) were obtained using the HepG2 cells, a human
hepatocytes cell line (Supplementary Fig. 1).
3.3. FXR activation restores the expression of genes involved in
glutamine and glutamate metabolism in rodent model of liver cirrhosis
Since development of chronic liver failure is often associated with
defects in glutamine/glutamate metabolism and urea cycle, which are
the primary cause of hyperammonemia, we have investigated whether
FXR plays a role in regulating in vivo metabolism of glutamine/
glutamate in a model of hepatic damage induced in mice by CCl4.
Results shown in Supplementary Fig. 2, demonstrate that 6 weeks
administration of CCl4 induces liver cirrhosis as demonstrated by liver
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Fig. 2. FXR−/− mice have an altered expression of glutamine and glutamate metabolism genes and present a phenotype characterized by an impaired synthesis of urea and by an
increased level of plasmatic ammonia. A, Liver mRNA from FXR+/+ and FXR−/−micewas extracted to perform Real-Time PCR for ASCT2, EAAT2, ASCT1, NAGS, GDH, CPSI, GLS and GS.
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amounts of N-acetylglutamate measured in FXR+/+ and FXR−/− mice. Data shown are the mean±SD of six mice per group. *Pb0.05 versus FXR+/+ mice.
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genes involved in glutamine and glutamate metabolism in these mice
demonstrates that histopathology features of liver cirrhosis associated0.0
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Table 2
Promoter analysis of human and mouse 5′ ﬂanking regions of glutamine and glutamate
metabolism genes.
Gene
(human)
Matrix:
FXRE_38
Position with
respect to the TSS
Score Sequence
GS Not found
GLS (liver) Not found
NAGS ER8 −476 0.73 TGAGCTcaggcaacAGGACA
GDH ER-8 −564 0.61 TGAGCGccctacagAGGCCA
CPSI Not found
ASCT1 ER-8 −473 0.64 TGTCCCagaaagagAGGAAA
ASCT2 IR-1 −737 0.66 AGGTGAaTGACTT
EAAT2 Not found
Gene
(mouse)
Matrix:
FXRE_38
Position with
respect to the TSS
Score Sequence
GS IR-1 −132 0.66 CGGCCAaTGGCCT
GLS (liver) ER-8 −974 0.66 TGGCCAcgaattcaAGGCCA
NAGS ER-8 −593 0.68 TGACCTtgaactcgTGGATA
NAGS ER-8 −41 0.65 TCACCTgtgggtggGGGGGA
GDH Not found
CPSI Not found
ASCT1 Not found
ASCT2 Not found
EAAT2 ER-8 −867 0.60 TGTCCCagtcctcgAGATAA
1528 B. Renga et al. / Biochimica et Biophysica Acta 1812 (2011) 1522–1531with CDCA resulted in an induction of the expression of ASCT1, EAAT2,
NAGS and GLS as well as suppression of GDH mRNA (Fig. 5A, n=6;
Pb0.05), while the expression of ASCT2, GS and CPSI was unaffected
(Fig. 5A, n=6, Pb0.05). As illustrated in Fig. 5B and C, in comparison
with naive animals, CCl4-treated mice had signiﬁcant lower plasma
levels of urea but increased levels of ammonia. These biochemical
abnormalities were corrected by treatment with CDCA (Fig. 5B and C,
n=6; Pb0.05). All together these data illustrates that in vivo activation
of FXR regulates the expression of genes involved in glutamine/
glutamate metabolism and stimulates urea synthesis and ammonia
detoxiﬁcation in a rodent model of cirrhosis.N
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the NAGS promoter
Having shown that FXR regulates genes involved in glutamine/
glutamate metabolism in tissues of murine and human origin, we
have then searched for putative FXR responsive elements in the
promoters of these genes. The NUBIScan analysis (http://www.
nubiscan.unibas.ch) of the 5′ ﬂanking regions (1000 base pairs
upstream to the transcriptional start site — TSS) of human and
mouse ASCT1, EAAT2, ASCT2, NAGS, GDH, CPSI, GLS and GS revealed
the presence of putative FXR responsive sequences such as IR-1 and
ER-8 in these promoters. However, only the NAGS gene has an FXRE
conserved among the two species, an ER-8 sequence located at−476
base pairs with respect to the transcriptional start site ATG in the
human NAGS promoter and at −593 base pairs in the murine
promoter (Table 2). For practical reasons (i.e. ease of transfection,
rapid replication and achievement of high number of cells to perform
molecular experiments such as chromatin immunoprecipitation and
EMSA) we have decided to assess the functionality of this ER-
8 sequence in HepG2 cells instead of primary cultures of hepatocytes.
To verify the hypothesis that FXR binds this ER-8 sequence, we have
performed an EMSA experiment with a biotin-labeled ER-8 probe
incubated with nuclear extracts obtained from HepG2 cells left
untreated or primed with 50 μmol/L CDCA for 18 h. As shown in
Fig. 6A this probe effectively binds nuclear extracts of unstimulated
cells and CDCA treatment increased this interaction. We conﬁrmed
the speciﬁcity of this binding by adding 250 fold excess of unlabeled
ER-8 probe or 1 μg FXR antibody. These approaches resulted in a
complete abrogation of the binding of the ER-8 biotin labeled probe to
the HepG2 nuclear extracts. Additionally, as shown in Fig. 6B, a ChIP
assay conducted in serum-starved HepG2 cells exposed to CDCA
demonstrated that FXR binds to a region in the NAGS promoter
containing the above mentioned ER-8 sequence (n=4; Pb0.05).
The functional role of this interaction in regulating NAGS expression
was further examined in transactivation experiments. First, a region- + - +
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(−558/−332) was ampliﬁed by PCR and cloned into a pGL3 promoter
vector. Using this reporter vector we have transfected HepG2 cells with
different concentrations of the plasmid pSG5-FXR (50, 100 and 200 ng)
in the presence of the heterodimeric partner RXR. As shown in Fig. 7A,
transient transfection assays revealed a dose-dependent activation of
the NAGS promoter (Fig. 7A, n=4, Pb0.05). As expected, the
mutagenesis of the ER8 sequence in the context of the NAGS promoter
prevented its activation by FXR (Fig. 7B). In order to conﬁrm these
results,we have cloned three copies of theNAGS ER-8 sequence or three
copies of the mutated ER-8 (TGTTCTcaggcaacATTACA) into a pGL3
promoter vector (pGL3(ER8)3X or a pGL3(ER8mut)3X). Using these
reagents we have carried out luciferase experiments in HepG2 cells
transfected with pSG5-FXR and pSG5-RXR expression vectors and then
treated with CDCA (10 μmol/L) or GW4064 (5 μmol/L) for 18 h. As
shown in Fig. 7C, in the presence of the luciferase reporter containing
three repeats of the wild type sequence ER-8, cotransfection with FXR
and RXR, per sewas able to induce an≈2 fold increase in the luciferase
activity (Fig. 7C, n=4, column 1 versus 2, Pb0.05) and the treatment0
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of four experiments.with the natural or synthetic FXR ligand resulted in an ≈3/4 fold
increase in luciferase activity (column 1 versus 3 and 4, Pb0.05). By
contrast, when HepG2 cells were transfectedwith pSG5-FXR and pSG5-
RXR expression vectors in the presence of the luciferase reporter
containing three tandem repeats of the ER-8 mutated sequence the
transactivation of FXR was completely abrogated in both unstimulated
and stimulated conditions (Fig. 7D, n=4). Overall, these results
demonstrated that the response element ER-8 in the NAGS promoter
is crucial for the FXR dependent induction of NAGS.
4. Discussion
Chronic liver disorders are traditionally characterized by an
impaired liver function caused by various factors such as nodular
regeneration of hepatocytes, altered expression of genes involved in
glutamine and glutamate metabolism, altered liver perfusion con-
tributed by porto-systemic shunting, and progressive disturbance of
liver urea metabolism leading to accumulation of ammonia in the
blood and tissues. [18–20]. The molecular mechanisms that lead to- - + -
0
25000
50000
75000
100000
125000
150000
pGL3(ER8mutated) 3X
pGL3(ER8mutated) 3X FXR/RXR
GW4064 5 μmol/L
- CDCA 10 μmol/L
R
LU
/βg
al
R
LU
/βg
al
B
D
-
0
50000
100000
150000
200000
FXR/RXR
+--
n NAGS 5′ﬂanking region (−558/−332) in HepG2 cells not trasfected or trasfected with
ments. *Pb0.05 versus pGL3(−558/−332)NAGS trasfected cells. B, Luciferase activity of
ls not trasfected or trasfected with 50, 100 and 200 ng of pSG5-FXR and pSG5-RXR were
nce were cloned into pGL3 vector. HepG2 cells were transfected with the pGL3(ER8)3x
ectors. 24 hours post transfection cells were stimulated with 10 μmol/L CDCA or with
tosidase activities. Data are the mean±SD of four experiments. *Pb0.05 versus pGL3
RXR expressing vectors. D, Three tandem repeats of the ER-8 mutated sequence were
sidase alone or in combination pSG5FXR and pSG5-RXR. 24 hours post transfection cells
hown as the ratio of luciferase to β-galactosidase activities. Data shown are themean±SD
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understood.
In the present study we provide compelling evidence for a
regulatory role of bile acids on glutamine/glutamate metabolism
and urea detoxiﬁcation by activation of the nuclear receptor FXR.
Support to this notion comes from the observation that mice
harboring a disrupted FXR gene develop hyperammonemia in
association with reduced blood levels of urea. This phenotype
associates with an altered liver expression of genes encoding for
proteins involved in glutamine and glutamate metabolism. Thus, we
found that while the expression of glutamine transporter ASCT2,
glutaminase and NAGS was signiﬁcantly downregulated in the liver of
FXR−/− mice, the expression of the glutamate transporter EAAT2,
ASCT1 and CPSI and glutamine synthase was unchanged in FXR−/−
mice with respect to the wild type strain. By contrast, the relative
expression of GDH mRNA was induced by≈3 fold. Overall these data
conﬁrmed that depletion of FXR in vivo sufﬁces per se to drive an
altered expression of genes involved in glutamine and glutamate
metabolism and conﬁrmed previous studies establishing that the
glutamine transporter ASCT2 is directly regulated by the activation of
FXR [14]. Support to this view comes also from the ﬁnding that ex vivo
treatment of primary mouse hepatocytes isolated from FXR+/+ mice
with CDCA or GW-4064 regulates the expression of genes involved in
glutamine and glutamate metabolism and enhances the urea
synthesis in these cells. Importantly, these regulatory effects were
completely lost in primary hepatocytes isolated from FXR−/− mice,
strongly indicating an essential role for FXR in mediating adaptive
changes of these genes in response to bile acids. Similar results were
obtained using HepG2 cells stimulated with CDCA or GW-4064.
Since these data suggest that FXR exerts a regulatory role on genes
involved in glutamine and glutamate metabolism – assuming the use
of FXR ligands in the treatment of ammonia disorders –we have next
investigated whether the expression of genes involved in glutamine
and glutamate metabolism is modulated in a rodent model of liver
cirrhosis. The results of these experiments conﬁrmed that the
development of hyperammonemia in CCl4 mice associates with a
reduction of blood urea concentrations along with a severe reduction
in the liver expression of NAGS and EAAT2 mRNA. By contrast, the
relative mRNA expression of ASCT2 and GDH appeared induced while
the mRNA expression of ASCT1, CPSI, GLS and GS was apparently
unchanged in CCl4 mice. Importantly, we found that the levels of
NAGS, ASCT1, EAAT2, GLS and GDH were regulated by treating mice
with an FXR ligand. Indeed, EAAT2, ASCT1, NAGS and GLS were
induced while GDH was downregulated in CCl4 mice administered
with an FXR ligand. Overall, the regulation of these genes by CDCA
associates with an increased synthesis of urea and a restored
ammonia detoxiﬁcation in cirrhotic mice.
Deﬁciency of N-acetylglutamate is the most severe of the urea
cycle disorders [21,22] leading to severe reduction of the CPS-I
activity, the ﬁrst enzyme, and limiting step, of urea cycle. Indeed,
deﬁciency of CPS-I impairs conversion of ammonia into carbamyl
phosphate, blocking the synthesis of urea. In noncirrhotic settings,
NAGS deﬁciency is biochemically characterized by an increased level
of plasmatic ammonia, whereas the concentration of other urea-cycle
intermediates is low or normal [21,22]. The majority of patients with
NAGS deﬁciency caused by frameshift or nonsense mutations have
b5% residual activity [23–25]. Complete NAGS deﬁciency leads to
hyperammonemia in the newborn period and subjects that are
successfully rescued from crisis are chronically at risk for repeated
bouts of hyperammonemia [23–25]. It has been recently demonstrat-
ed that derivatives of L-glutamic acid, in particular, N-carbamyl-
glutamate could activate the biosynthesis of carbamyl phosphate by
CPS-I, thus restoring, at least partially, the synthesis of urea in patients
with NAGS deﬁciency [26,27].
In the present study we have demonstrated that the FXR/RXR
heterodimer binds speciﬁcally to an ER8 sequence located at−476 bpfrom the transcriptional start site ATG in thehumanNAGSpromoter. The
characterization of the functionality of this ER8was obtained by both gel
mobility shift and ChIP assay. Further on, mutagenesis experiments
demonstrated that the FXR/RXR heterodimer becomes unable to induce
luciferase activity when this ER8 sequence was mutated. In aggregate,
these data established that NAGS is an FXR regulated gene and that
regulation of expression of this gene by FXR ismediated via activation of
an ER8 sequence. All together these molecular data are of clinical
relevancebecausean inducer ofNAGSmightholdutility in the treatment
of hyperammonia in chronic liver disorders. The identiﬁcation of NAGS
as direct FXR targets is consistent with results of genome wide analysis
indicating that approximately 25% of genes involved in amino acid and
nitrogen metabolism are potential targets for FXR [28].
In conclusion, the present study describes for the ﬁrst time that
FXR activation regulates genes involved in the glutamine and
glutamate metabolism (i.e. genes involved in the glutamine and
glutamate uptake, conversion of glutamine into glutamate and
glutamate into NAG) and enhances urea synthesis in hepatocytes.
Thus, activation of FXR could be beneﬁcial for the treatment of
hyperammonemia in chronic liver diseases.
Appendix A. Supplementary data
Supplementary data to this article can be found online at doi:10.
1016/j.bbadis.2011.06.009.
References
[1] D. Yang, H. Brunengraber, Glutamate, a window on liver intermediary metabo-
lism, J. Nutr. 130 (4S Suppl.) (2000) 4S–991.
[2] M. Watford, Glutamine and glutamate metabolism across the liver sinusoid, J.
Nutr. 130 (4S Suppl.) (2000) 7S–983.
[3] A. Braeuning, C. Ittrich, C. Köhle, S. Hailﬁnger, M. Bonin, A. Buchmann, et al.,
Differential gene expression in periportal and perivenous mouse hepatocytes,
FEBS J. 273 (22) (2006) 5051–5061.
[4] M.E. Brosnan, J.T. Brosnan, Hepatic glutamate metabolism: a tale of 2 hepatocytes,
Am. J. Clin. Nutr. 90 (3) (2009) 61S–857S.
[5] H. Morizono, L. Caldovic, D. Shi, M. Tuchman, Mammalian N-acetylglutamate
synthase, Mol. Genet. Metab. (Suppl. 1) (2004) S4–S11.
[6] A. Plaitakis, I. Zaganas, Regulation of human glutamate dehydrogenases:
implications for glutamate, ammonia and energy metabolism in brain, J. Neurosci.
Res. 66 (5) (2001) 899–908.
[7] P.M. Beart, R.D. O'Shea, Transporters for L-glutamate: an update on their
molecular pharmacology and pathological involvement, Br. J. Pharmacol. 150
(1) (2007) 5–17.
[8] S. Fiorucci, A. Mencarelli, E. Distrutti, G. Palladino, S. Cipriani, Targetting farnesoid-
X-receptor: frommedicinal chemistry to disease treatment, Curr. Med. Chem. 17 (2)
(2010) 139–159.
[9] M. Trauner, T. Claudel, P. Fickert, T. Moustafa, M. Wagner, Bile acids as regulators
of hepatic lipid and glucose metabolism, Dig. Dis. 28 (1) (2010) 220–224.
[10] S. Fiorucci, A. Mencarelli, G. Palladino, S. Cipriani, Bile-acid-activated receptors:
targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders, Trends
Pharmacol. Sci. 30 (11) (2009) 570–580.
[11] B. Renga, A. Mencarelli, P. Vavassori, V. Brancaleone, S. Fiorucci, The bile acid
sensor FXR regulates insulin transcription and secretion, Biochim. Biophys. Acta
1802 (3) (2010) 363–372.
[12] S. Fiorucci, S. Cipriani, A. Mencarelli, B. Renga, E. Distrutti, F. Baldelli, Counter-
regulatory role of bile acid activated receptors in immunity and inﬂammation,
Curr. Mol. Med. 10 (6) (2010) 579–595.
[13] P.A. Edwards, H.R. Kast, A.M. Anisfeld, BAREing it all: the adoption of LXR and FXR
and their roles in lipid homeostasis, J. Lipid Res. 43 (1) (2002) 2–12.
[14] C.I. Bungard, J.D. McGivan, Identiﬁcation of the promoter elements involved in the
stimulation of ASCT2 expression by glutamine availability in HepG2 cells and the
probable involvement of FXR/RXRdimers, Arch. Biochem. Biophys. 443 (1–2) (2005)
53–59.
[15] C.J. Sinal, M. Tohkin, M. Miyata, J.M. Ward, G. Lambert, F.J. Gonzalez, Targeted
disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid
homeostasis, Cell 102 (2000) 731–744.
[16] T. Mutsvangwa, J.G. Buchanan-Smith, B.W. McBride, Effects of ruminally
degradable nitrogen intake and in vitro addition of ammonia and propionate on
the metabolic fate of L-[1-14C]alanine and L-[15N]alanine in isolated sheep
hepatocytes, J. Anim. Sci. 75 (4) (1997) 1149–1159.
[17] Y. Ohtake, M.G. Clemens, Interrelationship between hepatic ureagenesis and
gluconeogenesis in early sepsis, Am. J. Physiol. 260 (3 Pt 1) (1991) E453–E458.
[18] S.W. Brusilow, N.E. Maestri, Urea cycle disorders: diagnosis, pathophysiology, and
therapy, Adv. Pediatr. 43 (1996) 127–170.
[19] R. Jalan, D. Shawcross, N. Davies, The molecular pathogenesis of hepatic
encephalopathy, Int. J. Biochem. Cell Biol. 35 (2003) 1175–1181.
1531B. Renga et al. / Biochimica et Biophysica Acta 1812 (2011) 1522–1531[20] O. Braissant, Current concepts in the pathogenesis of urea cycle disorders, Mol.
Genet. Metab. 100 (Suppl 1) (2010) S3–S12.
[21] J.P. Colombo, N-acetylglutamate synthetase (NAGS) deﬁciency, Adv. Exp. Med.
Biol. 368 (1994) 135–143.
[22] L. Caldovic, N. Ah Mew, D. Shi, H. Morizono, M. Yudkoff, M. Tuchman, N-
acetylglutamate synthase: structure, function and defects, Mol. Genet. Metab.
100 (Suppl. 1) (2010) S13–S19.
[23] L. Caldovic, H. Morizono, M. Tuchman, Mutations and polymorphisms in the human
N-acetylglutamate synthase (NAGS) gene, Hum. Mutat. 28 (2007) 754–759.
[24] C. Bachmann, J.P. Colombo, K. Jaggi, N-acetylglutamate synthetase (NAGS)
deﬁciency: diagnosis, clinical observations and treatment, Adv. Exp. Med. Biol.
153 (1982) 39–45.[25] J. Haberle, E. Schmidt, S. Pauli, J.G. Kreuder, B. Plecko, A. Galler, et al., Mutation
analysis in patients with N-acetylglutamate synthase deﬁciency, Hum. Mutat. 21
(2003) 593–597.
[26] J. Hinnie, J.P. Colombo, B. Wermuth, F.J. Dryburgh, N-acetylglutamate synthetase
deﬁciency responding to carbamylglutamate, J. Inherit. Metab. Dis. 20 (1997)
839–840.
[27] A.A. Morris, S.W. Richmond, S.J. Oddie, M. Pourfarzam, V. Worthington, J.V.
Leonard, N-acetylglutamate synthetase deﬁciency: favourable experience with
carbamylglutamate, J. Inherit. Metab. Dis. 21 (1998) 867–868.
[28] A.M. Thomas, S.N. Hart, B. Kong, J. Fang, X.B. Zhong, G.L. Guo, Genome-wide tissue-
speciﬁc farnesoid X receptor binding in mouse liver and intestine, Hepatology
51 (4) (2010) 1410–1419.
